Tumors are not supposed to have their own nerve supply. Healthy tissue grows nerves through carefully regulated developmental signals, but cancer isn't healthy tissue, and a study published in Cell Death & Differentiation, reported publicly starting August 14, 2026, shows that triple-negative breast cancer has found a genuinely devious workaround: recruiting the body's own immune cells to build that nerve supply for it.

A cancer subtype that already has few good options

Triple-negative breast cancer earns its name from what it lacks: the estrogen receptor, progesterone receptor, and HER2 protein that define most other breast cancer subtypes, and that also happen to be the specific molecular targets most existing breast cancer drugs are designed to attack. Without any of those three targets present, triple-negative tumors are left considerably harder to treat with the hormone-blocking and HER2-targeted therapies that have transformed outcomes for other forms of the disease, making it one of the more aggressive and treatment-resistant breast cancer subtypes clinicians currently face.

Researchers from the University of Oklahoma, led by a team that included first author Jacob W. Farriester and senior author Maureen A. Cox, set out to understand a phenomenon that has puzzled cancer biologists for years: how tumors manage to recruit peripheral nerves into their own tissue in the first place, a process called axonogenesis, and what role that recruited nerve supply actually plays once it's established.

The immune cell that isn't supposed to help cancer

Tumor-infiltrating nerves have already been linked in prior research to worse outcomes across several cancer types, associated with faster tumor growth, greater capacity to spread, and increased resistance to treatment. What remained unclear was the specific biological mechanism driving nerves to grow into tumor tissue in the first place, since earlier laboratory studies had suggested tumor cells themselves might directly release growth signals capable of attracting nearby nerves, but that mechanism had never actually been confirmed happening inside a living organism.

The Oklahoma team's findings point to a different, and in some ways more troubling, answer. Rather than tumor cells signaling directly to nerves, the research shows that tumors first recruit macrophages, immune cells whose normal job involves fighting infection and helping repair damaged tissue, into the surrounding tumor microenvironment. Once inside that environment, these macrophages release brain-derived neurotrophic factor, commonly abbreviated BDNF, a protein best known for supporting the growth and survival of nerve cells within the brain. In healthy tissue, BDNF plays a genuinely beneficial role in neural development and maintenance. Inside a triple-negative breast tumor, according to the study, that same signal gets co-opted to draw nearby peripheral nerves directly into the cancer itself.

Turning a healing signal into a growth engine

That hijacking represents the study's central and most significant finding: cancer isn't inventing an entirely new biological mechanism to build its own nerve supply, it's redirecting an existing, normally protective signaling pathway toward its own benefit. Macrophages recruited into the tumor microenvironment would, under ordinary circumstances, be there to help clear damaged or abnormal tissue. Instead, the tumor appears to manipulate their function, turning cells whose presence should theoretically work against the cancer into active participants helping the tumor build the neural infrastructure it needs to grow more effectively.

Once nerves have been drawn into the tumor through this macrophage-mediated BDNF signaling, the researchers found evidence that those nerves may then actively contribute to the cancer's progression, potentially helping it grow faster, resist treatment more effectively, and spread to other locations in the body, consistent with the pattern seen in prior research linking tumor innervation broadly to worse cancer outcomes across multiple tumor types.

Confirming the mechanism actually happens in living tissue

A key contribution of this specific study, distinguishing it from earlier laboratory work suggesting a related but unconfirmed mechanism, is that the Oklahoma team demonstrated this macrophage-to-nerve signaling pathway occurring in vivo, meaning within a living biological system rather than solely in isolated cell cultures. Prior research had suggested tumor cells themselves might release BDNF directly to attract nerves, based on laboratory dish experiments, but according to the study's authors, that direct tumor-cell-to-nerve signaling pathway had never actually been demonstrated occurring inside a living organism.

By instead identifying macrophages as the actual intermediary cell type responsible for producing the BDNF signal driving nerve recruitment, and confirming that pathway in a living system, the research offers a considerably more complete and biologically grounded picture of how tumor innervation actually unfolds in practice, rather than relying on a mechanism inferred primarily from simplified laboratory conditions.

Why identifying the actual cellular source matters for treatment

Beyond its value as basic biological insight, pinpointing macrophages specifically, rather than tumor cells directly, as the source of the BDNF signal driving nerve recruitment carries genuine therapeutic implications. If tumor cells themselves were the direct source of the signal, targeting that pathway would require finding a way to interfere with the cancer cells' own protein production without disrupting healthy tissue nearby. Identifying macrophages as an intermediary step instead opens up a different category of potential intervention: therapies designed to interrupt macrophage recruitment into the tumor microenvironment in the first place, or to specifically block BDNF release from macrophages once they've arrived, without needing to directly target the cancer cells' own internal signaling machinery.

That distinction matters considerably given how much broader cancer research has already invested in understanding and manipulating tumor-associated macrophage behavior across multiple cancer types, since macrophages have become an increasingly prominent target for cancer immunotherapy research generally. A treatment strategy built around disrupting macrophage-driven BDNF signaling specifically could potentially draw on that broader existing research infrastructure, rather than requiring an entirely novel therapeutic approach built from scratch.

What this adds to a broader shift in how cancer biology gets studied

This study fits within a growing area of cancer research sometimes referred to as cancer neuroscience, examining the surprisingly active and consequential relationship between tumors and the nervous system, a field that has gained considerable momentum in recent years as researchers have increasingly recognized that nerves aren't simply passive bystanders near tumor tissue but can actively participate in and influence cancer progression. The Oklahoma team's specific contribution, identifying the macrophage-BDNF pathway as a driver of that nerve recruitment process in triple-negative breast cancer specifically, adds a concrete, mechanistically detailed piece to that broader and still-developing picture.

What still needs to happen before this reaches patients

As with most foundational cancer biology research, translating this specific mechanistic discovery into an actual clinical treatment remains a considerably longer process than identifying the underlying pathway itself. The current findings establish that macrophage-derived BDNF drives nerve recruitment into triple-negative breast tumors and that this recruited nerve supply appears to support tumor growth, but confirming that disrupting this specific pathway therapeutically actually improves patient outcomes would require additional preclinical testing followed by clinical trials, a process that typically spans years even for well-characterized biological targets.

Given how limited existing treatment options remain for triple-negative breast cancer specifically, a genuinely new and mechanistically distinct target, one operating through immune cell manipulation rather than the hormone or HER2 pathways existing drugs already address, offers researchers a meaningfully different direction to pursue for a cancer subtype that has historically had fewer targeted therapy options than most other forms of breast cancer.

---

*Sources cited in this article include the peer-reviewed study "Macrophage-secreted brain-derived neurotrophic factor promotes tumor growth in triple-negative breast cancer by inducing axonogenesis," published in Cell Death & Differentiation, and reporting from ScienceDaily covering research led by Jacob W. Farriester and Maureen A. Cox at the University of Oklahoma. All figures reflect reporting available as of August 17, 2026.*